Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1Tihamer Orban, Liping Yu, Jerry P. Palmer et al.|Diabetes Care|2009Cited by 260
Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trialHiddo J.L. Heerspink, Janet B. McGill, Andreas L. Birkenfeld et al.|Diabetes Research and Clinical Practice|2023Cited by 57
Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetesVikas S. Sridhar, David Z.I. Cherney, Christine P. Limonte et al.|Diabetologia|2023Cited by 25
875-P: Baseline Characteristics for FINE-ONE—A Randomized Phase III Trial Assessing Finerenone in People with T1D and CKDHiddo J.L. Heerspink, Andreas L. Birkenfeld, David Cherney et al.|Diabetes|2025Cited by 0